Medicare to retain Avastin coverage for breast cancer patients

06/30/2011 | ABC News

Medicare will continue paying for Avastin, produced by Roche Holding's Genentech unit, as a treatment for breast cancer, even if the FDA decides to revoke its conditional approval, said CMS spokesman Don McLeod. An FDA advisory committee voted unanimously to remove this indication, though the final decision rests with FDA Commissioner Dr. Margaret Hamburg. "The drug will still be on the market, doctors will still be prescribing it, and we will continue to pay for it," McLeod said.

View Full Article in:

ABC News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD